Designing A Better Future For Immuno-Oncology: The Power Of ‘Iterative Innovation’
Insights From Peter Sandor, Primary Focus Lead IO, Astellas Pharma
We are at a pivotal point in the reassessment of our approach to innovation, with the value of ‘design thinking’ and an ‘iterative innovation approach’ becoming the most promising solutions to solving the scientific and biological challenges of the future.
You may also be interested in...
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
At ESMO, data showed overall response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.